Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671865 · ClinicalTrials.gov registry record
Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
A clinical trial of Facioscapulohumeral Muscular Dystrophy, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT01671865 is a study of Facioscapulohumeral Muscular Dystrophy that is active but no longer recruiting, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 75 participants, below the 1,500-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01671865, a study of Facioscapulohumeral Muscular Dystrophy, is active but no longer recruiting, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to identify and study changes in muscle in people with facioscapulohumeral muscular dystrophy using magnetic resonance imaging and spectroscopy.
Conditions Studied
Study Locations (1)
Maryland
- Doris Leung - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2012-03 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671865
The ClinicalTrials.gov registry entry for NCT01671865 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,500-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (95% lower). The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Facioscapulohumeral Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT01671865 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01671865 about?
NCT01671865 is a clinical study titled "Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy". The purpose of this research study is to identify and study changes in muscle in people with facioscapulohumeral muscular dystrophy using magnetic resonance imaging and spectroscopy.
What is the current status of trial NCT01671865?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2012-03. Estimated completion is 2026-06.
What conditions does trial NCT01671865 study?
This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy.
Who is sponsoring clinical trial NCT01671865?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01671865 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facioscapulohumeral Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
RECRUITING
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
RECRUITING · Phase 1
-
BetterLife FSHD: A Patient-driven Health and Research Platform
RECRUITING
-
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.